SLC5A2 and chronic kidney disease: The introduction of sodium-glucose cotransporter-2-inhibitors (SGLT2i) has positively affected the outcomes of patients suffering from type 2 diabetes (T2D) [1,2], chronic kidney disease (CKD) [3], and congestive heart failure (CHF) [4,5].